Anti-SARS-CoV-2 immunoglobulin

DB16360InvestigationalProtein Based Therapies

Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG) is obtained from the plasma of patients who recover from COVID-19 and develop neutralizing antibodies. Anti-coronavirus immunoglobulin is derived from COVID-19 convalescent plasma(https://go.drugbank.com/drugs/DB15692) but contains...

Mechanism: Pharmacologically active on Spike glycoprotein
Curator reviewed
Also known as: Anti-Coronavirus immunoglobulin · Anti-COVID-19 hyperimmune globulin (human) · COVID-HIG · GC5131 · hIVIG
Code names: Anti-SARS-CoV-2 immunoglobulin

Resolves to

Compound

UNIIVF62JD6WN3

Targets

P0DTC2S

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

7Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Anti-SARS-CoV-2 immunoglobulin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account